216 related articles for article (PubMed ID: 1380646)
1. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
Zhen W; Link CJ; O'Connor PM; Reed E; Parker R; Howell SB; Bohr VA
Mol Cell Biol; 1992 Sep; 12(9):3689-98. PubMed ID: 1380646
[TBL] [Abstract][Full Text] [Related]
2. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells.
Jones JC; Zhen WP; Reed E; Parker RJ; Sancar A; Bohr VA
J Biol Chem; 1991 Apr; 266(11):7101-7. PubMed ID: 2016318
[TBL] [Abstract][Full Text] [Related]
3. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.
Johnson SW; Perez RP; Godwin AK; Yeung AT; Handel LM; Ozols RF; Hamilton TC
Biochem Pharmacol; 1994 Feb; 47(4):689-97. PubMed ID: 8129746
[TBL] [Abstract][Full Text] [Related]
4. Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin.
May A; Nairn RS; Okumoto DS; Wassermann K; Stevnsner T; Jones JC; Bohr VA
J Biol Chem; 1993 Jan; 268(3):1650-7. PubMed ID: 8420940
[TBL] [Abstract][Full Text] [Related]
5. Gene-specific DNA repair of interstrand cross-links induced by chemotherapeutic agents can be preferential.
Larminat F; Zhen W; Bohr VA
J Biol Chem; 1993 Feb; 268(4):2649-54. PubMed ID: 8428941
[TBL] [Abstract][Full Text] [Related]
6. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
7. Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage.
Larminat F; Bohr VA
Nucleic Acids Res; 1994 Aug; 22(15):3005-10. PubMed ID: 8065913
[TBL] [Abstract][Full Text] [Related]
8. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity.
Petersen LN; Mamenta EL; Stevnsner T; Chaney SG; Bohr VA
Carcinogenesis; 1996 Dec; 17(12):2597-602. PubMed ID: 9006094
[TBL] [Abstract][Full Text] [Related]
9. Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts.
Calsou P; Frit P; Salles B
Nucleic Acids Res; 1992 Dec; 20(23):6363-8. PubMed ID: 1475197
[TBL] [Abstract][Full Text] [Related]
10. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
[TBL] [Abstract][Full Text] [Related]
11. Repair of ribosomal RNA genes in hamster cells after UV irradiation, or treatment with cisplatin or alkylating agents.
Stevnsner T; May A; Petersen LN; Larminat F; Pirsel M; Bohr VA
Carcinogenesis; 1993 Aug; 14(8):1591-6. PubMed ID: 8353843
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.
Moufarij MA; Phillips DR; Cullinane C
Mol Pharmacol; 2003 Apr; 63(4):862-9. PubMed ID: 12644587
[TBL] [Abstract][Full Text] [Related]
13. Deficient gene specific repair of cisplatin-induced lesions in Xeroderma pigmentosum and Fanconi's anemia cell lines.
Zhen W; Evans MK; Haggerty CM; Bohr VA
Carcinogenesis; 1993 May; 14(5):919-24. PubMed ID: 8504485
[TBL] [Abstract][Full Text] [Related]
14. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Yang LY; Li L; Keating MJ; Plunkett W
Mol Pharmacol; 1995 May; 47(5):1072-9. PubMed ID: 7746274
[TBL] [Abstract][Full Text] [Related]
15. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
Hill BT; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Bedford P
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):75-83. PubMed ID: 2380098
[TBL] [Abstract][Full Text] [Related]
16. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
[TBL] [Abstract][Full Text] [Related]
19. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
Shellard SA; Hosking LK; Hill BT
Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
[TBL] [Abstract][Full Text] [Related]
20. Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and -resistant adenocarcinoma cells.
Talarico T; Cullinane CM; Gray PJ; Webster LK; Deacon GB; Phillips DR
Anticancer Drug Des; 2001; 16(2-3):135-41. PubMed ID: 11962511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
